This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Defying Industry Trends, BBK Worldwide Expands Ownership From Within

NEWTON, Mass., March 21, 2013 /PRNewswire/ -- In an industry increasingly defined by mergers and acquisitions, BBK Worldwide (BBK) is bucking the trend by creating ownership opportunities from within. Celebrating 30 years, BBK remains one of the only independent and self-funded patient recruitment agencies, and is able to offer its global pharmaceutical and medical device clients levels of flexibility and creative innovation unmatched by its competitors. This history of vision and leadership has led BBK to name four additional principals who, together, will assume a minority ownership in the company. All long-serving employees, Matthew Kibby, Rob Laurens, Liz Ritchie, and Matthew Stumm have played key roles in shaping the company's success as the global leader in patient recruitment for the clinical R&D segment of the pharma, biotech, and medical device industries. As principals, they will partner with BBK's founding principals Joan F. Bachenheimer and Bonnie A. Brescia to maintain the company's core mission and values while driving growth in key market areas.

"These four individuals have made unyielding contributions to BBK over the years -- contributions that have brought innovation and definition to the patient recruitment marketplace as a whole," comments Joan F. Bachenheimer, founding principal, BBK Worldwide. "Their new roles will allow for expanded growth in critical business areas, ensuring that current and future customers benefit from the most strategic and sophisticated thinking in the industry."

Each newly named principal will focus their efforts on expanding their current management areas. Matthew Stumm will draw upon his creative vision to drive innovation for Agency320, BBK's partner company responsible for creative and media services. Rob Laurens will apply his 19 years of industry knowledge to advance patient recruitment training and industry best practices. Liz Ritchie, BBK's third longest-serving employee, will continue to manage corporate and legal services. Matthew Kibby will apply his innovative mindset to expanding and refining product offerings from BBK's technology partner TCN Technologies and its hallmark product TrialCentralNet SM.

Companies often turn to mergers and acquisitions as a corporate strategy for creating growth, however, often at the expense of innovation. BBK's current move represents a deliberate shift from this industry trend. "Over the past 10 years, BBK has been approached by several different organizations interested in taking an outside investment in BBK," comments Bonnie A. Brescia, founding principal, BBK Worldwide. "We've taken a different approach that values the commitment and dedication of our employees. Our business model reflects our commitment to, and appreciation for, our employees and for their hard work and investment. This dynamic model creates opportunities to expand ownership from within."

Guided by the law firm of Morse, Barnes-Brown & Pendleton, PC, BBK was able to create a new corporate structure that also has the potential to seamlessly expand ownership opportunities to other deserved employees within the company -- further ensuring the retention of key talent and the viability of the company moving forward. "We're thrilled to be able to connect employees to the success of the company with this new model that provides customers with the most experienced and sophisticated patient recruitment support in the industry," comments Bachenheimer.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs